Navigation Links
Mast Therapeutics Reports Third Quarter 2013 Financial Results
Date:11/4/2013

SAN DIEGO, Nov. 4, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended September 30, 2013.

Brian M. Culley, Chief Executive Officer, said: "We continue to focus on EPIC, our pivotal phase 3 study of MST-188 in sickle cell disease.  We almost doubled the number of open clinical sites since the end of the second quarter and are approaching our goal of opening 40 clinical sites in the U.S. Beginning next year, we also plan to open approximately 30 clinical sites outside the U.S."

Mr. Culley continued: "In addition to sickle cell disease, we are evaluating MST-188 in other areas of significant unmet medical need and plan to initiate a 60-patient phase 2 study in acute limb ischemia in early 2014.  This study will determine whether MST-188 improves the effectiveness of existing thrombolytic agents, such as Activase®, a tissue plasminogen activator (tPA) that is approved to treat stroke, heart attack and pulmonary embolism.  If our phase 2 study demonstrates that MST-188 improves the 'clot busting' activity of tPA, we believe it will open the door to developing MST-188 in combination with tPA in all settings in which thrombolytics are used, most notably stroke." 

Third Quarter 2013 Operating ResultsThe Company's net loss for the third quarter of 2013 was $5.3 million, or $0.05 per share (basic and diluted), compared to a net loss of $3.2 million, or $0.07 per share (basic and diluted), for the same period in 2012.

Research and development (R&D) expenses for the third quarter of 2013 were $3.1 million, an increase of $1.4 million, or 87%, compared to $1.7 million for the same period in 2012. The increase was primarily due to increases of $1.3 million in external clinical study fees and expenses and $
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
2. Echo Therapeutics Schedules Third Quarter 2013 Financial Results for Thursday, November 7, 2013
3. G1 Therapeutics to Present at Southeast BIO Investor & Partnering Forum
4. Cell Therapeutics Reports Third Quarter 2013 Financial Results
5. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
6. Abide Therapeutics Appoints Dr. Gary ONeill as Vice President of Biology
7. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
8. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
9. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
10. ISSYS Inc. will showcase its Titan Wireless Implantable Hemodynamic Monitor and its clinical study summary at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference (Booth 1638) in San Francisco (October 29 to 31, 2013)
11. Aratana Therapeutics Adds to Commercial Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... NxStage® Kidney Care, Inc ., a subsidiary of NxStage® Medical, ... the grand opening ceremony of its Oak Brook, ... Street on November 20, 2014 from 3pm – 7pm. The Oak ... are committed to providing patients with enhanced access to the ... more flexible dialysis treatment options.   The facility ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Electronic ... dramatically as a result of government initiatives and ... - healthcare providers have invested over the past ... heart of health IT, and U.S. clinicians use ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)...  Nektar Therapeutics (Nasdaq: NKTR ) will ... September 30, 2014 on Thursday, November 6, 2014, after ... , president and chief executive officer, will host a ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... Webcast of the conference call can be accessed through ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
... Ontario, April 18, 2011 GlaxoSmithKline (GSK) and Valeant ... 15 April 2011 to the U.S. Food and Drug ... 2010 for the New Drug Application (NDA) for ezogabine*. ... studied for the adjunctive treatment of adults with partial-onset ...
... TARRYTOWN, N.Y., April 18, 2011 Regeneron Pharmaceuticals, Inc. ... U.S. Food and Drug Administration (FDA) has accepted for ... Trap-Eye for the treatment of the neovascular form of ... the Company,s request for priority review of its BLA. ...
Cached Medicine Technology:Regulatory Update - GSK and Valeant Respond to FDA on ezogabine 2Regulatory Update - GSK and Valeant Respond to FDA on ezogabine 3FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 2FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 3
(Date:10/31/2014)... A new report by Milken Institute School of ... Washington University examines the challenge of maintaining enriched ... in Covered California and who are also eligible ... Program (CPSP). The CPSP, whose roots are in ... developed for low-income pregnant women, makes enriched maternity ...
(Date:10/30/2014)... Albert Einstein College of Medicine of ... will present their latest aging research at the ... Meeting. Topics include the identification of a genotype ... impairment and the cellular biology of aging. GSA ... Washington, D.C., "Einstein-Montefiore has distinguished itself in a ...
(Date:10/30/2014)... 2014—Analysis of data from an institutional patient registry ... local control, 79 percent of tumors, for medically ... SBRT from 2003 to 2012, according to research ... in Thoracic Oncology. The Symposium is sponsored by ... American Society for Radiation Oncology (ASTRO), the International ...
(Date:10/30/2014)... research group at the DFG Research Center for Regenerative ... Dresden (CRTD) demonstrated for the first time the in ... three dimensions from mouse embryonic stem cells. Correct spatial ... the dorsal/ventral axis was observed., This study has been ... Cell Reports " on 30.10.2014 ., For many years ...
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer ... and more, is currently hosting a sweepstakes on its ... is open to U.S. residents age 18 and over, ... One lucky winner will then be selected at random ... card to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba ...
Breaking Medicine News(10 mins):Health News:Report examines health care challenges for pregnant women enrolled in covered California 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Sustained local control for medically inoperable, early stage lung cancer patients 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 3Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2
... stress hormones may be disregulated in people with chronic ... that helps the body deal with physical and psychological ... stress hormone cortisol by the adrenal glands. ... tiredness. It's cause is not well understood, but some ...
... Hopkins University observed that a chest compression belt outperforms ... //When someone has a cardiac arrest, it's vital to ... soon as possible. Usually this is done by applying ... rhythm, but these are usually not available in those ...
... surgery for emphysema does not help the sickest patients, ... of the lungs - the alveoli - are progressively ... they cannot do everyday activities like climbing stairs or ... suggest that lung reduction surgery was beneficial for people ...
... high levels of C-reactive protein and low levels of albumin ... the 25% of patients who die while on kidney dialysis,// ... such patients run between five and one hundred times the ... population. ,Doctors at Johns Hopkins University have surveyed ...
... the dangers of getting a lung infection or irritation from a ... hot tub, or jacuzzi, at home or in a health club. ... clean// and well-maintained in order to avoid developing a problem with ... have investigated two patients presenting with 'hot tub lung' - a ...
... in the US have more hospital admissions for respiratory ... pollution and public health. Now doctors at the University ... on Medicare costs in a large group of the ... pollution measures in 185 metropolitan areas. They found that ...
Cached Medicine News:
An adhesive-backed hanger, designed for use where space is limited (fume hoods, sterile hoods, etc.). Sticks to any smooth, dry surface without damage. Resistant to chemicals and UV light....
Four Tiered Pipette Rack. Made for disposable plastic pipettes. Designed for removal of pipettes from the right side. Three tiered and left side removal racks are also available...
... Pipette Tracker is an automated solution ... calibration and performance testing for all pipettes ... directly from any balance Supports ... ISO 8655, DIN 12650, ISO 9000, NCCLS ...
... to configure for gravimetric calibration and is ... method or enter your own parameters (number ... automatically manages the calibration protocol with direct ... to the software, which establishes the calibration ...
Medicine Products: